epoetin alfa

Generic Name: epoetin alfa

Clinical Trials

Treatment of Anemia in Diabetic Subjects With CKD

Phase 2

Terminated

Conditions: Anemia

First Posted Date: 2005-10-18

Last Posted Date: 2011-06-10

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 11

Registration Number: NCT00240734

Randomized, Double-blind, Placebo-controlled Study to Assess Fatigue in Patients With ACD Due to RA Receiving PROCRIT

Phase 2

Terminated

Conditions: Anemia
Rheumatoid Arthritis

First Posted Date: 2005-10-12

Last Posted Date: 2011-06-10

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 29

Registration Number: NCT00236678

PROCRIT and Short-Term Outcomes in Orthopedic Surgery

Phase 2

Terminated

Conditions: Anemia
Surgery, Arthroscopy

First Posted Date: 2005-10-12

Last Posted Date: 2011-06-10

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 6

Registration Number: NCT00236405

A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia

Phase 2

Terminated

Conditions: Anemia
Aged
Hemoglobins

First Posted Date: 2005-09-29

Last Posted Date: 2011-06-10

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 9

Registration Number: NCT00228995

A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy

Phase 4

Completed

Conditions: Anemia
Neoplasms

First Posted Date: 2005-09-22

Last Posted Date: 2011-05-19

Lead Sponsor: Janssen-Cilag B.V.

Target Recruit Count: 110

Registration Number: NCT00216541

A Study to Confirm the Safety and Efficacy of Epoetin Alfa (PROCRIT) Administered Perioperatively vs. the Standard of Care in Blood Conservation in Patients Undergoing Major Elective Spinal Surgery (SPINE Study)

Phase 3

Completed

Conditions: Anemia
Venous Thrombosis

First Posted Date: 2005-09-21

Last Posted Date: 2011-06-10

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 680

Registration Number: NCT00211146

A Study to Evaluate the Impact of Maintaining Hemoglobin Levels Using Epoetin Alfa in Patients With Metastatic Breast Cancer Receiving Chemotherapy

Phase 3

Completed

Conditions: Anemia
Breast Neoplasms
Quality of Life

First Posted Date: 2005-09-21

Last Posted Date: 2010-11-30

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 939

Registration Number: NCT00211133

The Duration Study

Phase 3

Terminated

Conditions: Anemia

First Posted Date: 2005-09-21

Last Posted Date: 2011-06-10

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 2

Registration Number: NCT00210730

An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy.

Phase 2

Completed

Conditions: Anemia

First Posted Date: 2005-09-21

Last Posted Date: 2011-06-10

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 310

Registration Number: NCT00210834

Pharmacokinetic/ Pharmacodynamic Study of Epoetin Alfa (PROCRIT) in Critically Ill Patients.

Phase 2

Completed

Conditions: Anemia
Critical Illness

First Posted Date: 2005-09-21

Last Posted Date: 2011-06-10

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 60

Registration Number: NCT00210756

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.